N/A N=18 PharmacoMRI of Parkinson Disease
Parkinson's Disease
Primary: Correlation Coefficient Between UPDRS III Score and Independent Components Analysis Network Strength in Left Parietal Cortex. — 0.5869 unitless
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=113 A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
Motor OFF Episodes Associated With Parkinson's Disease
Primary: Change From Pre-dose to 90 Mins. Post-dose in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Score After 4 Weeks of Dosing in Each…
N/A N=37 Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD
Parkinson's Disease
Primary: L-DOPA Insensitivity — 5 Participants — p=0.00468
Phase 2 N=48 A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
Parkinson's Disease · Off Episodes of Parkinson Disease
Primary: Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method…
Phase 3 N=40 Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease
Parkinson Disease · Orthostatic Hypotension
Primary: Change in Systolic Blood Pressure From Supine to Tilt at 3 Minutes — -24.22; -20.32 mmHg
N/A N=42 Effect of Levodopa on Postural Motor Learning in Parkinson Disease
Parkinson Disease
Primary: Change in Movement of Center of Mass (COM) After Postural Perturbation — 0.31; 0.28; 0.32; 0.26 meters
Phase 4 N=40 Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
Parkinson's Disease
Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale
N/A N=60 Evaluation of a Millimeter Wave Emission Bracelet for Improving Parkinson's Disease Symptoms
Parkinson Disease
Primary: Assessment of the Effectiveness of Two Months of Use of the Remedee Endorphin Band Medical Device in Improving Motor Disorders in Patients With Parkinson's Disease — 6…
N/A N=9 Effect of Exercise in Parkinsonism
Parkinson's Disease · Drug-induced Parkinsonism
Primary: Change in Dopamine Transporter Imaging — 4.6; -15.9 % change in arbitrary intensity units
Phase 4 N=19 Vigor and the LDR in Parkinson Disease
Parkinson Disease
Primary: Tapping Speed Task - Experiment 1 — 110.52; 128.89; 138.43; 145.86 taps/min
Phase 2 N=90 Image Parkinson's Disease Progression Study
Parkinson's Disease
Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)
Phase 3 N=778 A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)
Parkinson Disease
Primary: Change From Baseline in Mean "Off" Time — -0.9; -0.9; -0.8; -0.8 Hours/day — p=0.8700
Phase 3 N=325 Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
Idiopathic Parkinson's Disease
Primary: Pulmonary Safety of CVT-301 Change From Baseline for FEV1. — 2.957; 3.117; -0.059; -0.078 Liters
N/A N=57 Aerobic Exercise in Parkinson's Disease
Parkinson's Disease
Primary: Change in MDS-UPDRS Part III Motor (OFF) Score — 0.44; -2.96 score on scale — p=>0.05
Phase 2 N=28 Transcranial Magnetic Stimulation to Treat Parkinson's Disease
Parkinson Disease
Primary: Gait Speed — 8.35; 8.41; 25.84; 8.80 seconds
Phase 3 N=339 Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
Idiopathic Parkinson's Disease
Primary: Unified Parkinson's Disease Rating Scale (UPDRS) Part III — -9.83; -5.91 units on a scale
N/A N=15 The Impact of Exercise on Subthalamic Nucleus Neural Activity in Parkinson's Disease
Parkinson Disease · Deep Brain Stimulation
Primary: Finger Tapping — 3; 3; 3; 3 score on a scale
N/A N=30 Investigating Central Neurophysiologic Correlates of Non-Motor Symptoms of Parkinson's Disease
Parkinson Disease · Autonomic Dysfunction · Depression
Primary: Change in Frontal Midline Theta EEG Power After Brain Stimulation — 1.03; 0.44; 1.01 microvolts^2/Hz — p=0.08
N/A N=20 Effects of Neuromodulation and Rehabilitation of the Locomotor Network in Freezing of Gait
Parkinson Disease With Freezing of Gait
Primary: Change in Functional Connectivity to the Supplementary Motor Area. — -.176; .190 z-score
Phase 3 N=141 Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
Parkinson Disease, Off Episodes
Primary: Mean Change From Pre-Dose to 30 Minutes Post-Dose in The Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Motor Examination (MDS-UPDRS Part…
N/A N=62 Repetitive Transcranial Magnetic Stimulation for Musculoskeletal Pain in Patients With Parkinson's Disease
Parkinson's Disease · Musculoskeletal Pain · Repetitive Transcranial Magnetic Stimulation
Primary: Change From Baseline Over 2 Months (Group by Time Interaction) in Modified KING'S PD Pain Scale Domain 1 — 12.41; 13.64; 9.96; 14.71 units on a scale
N/A N=63 Effect of Mental Imagery Training on Brain Plasticity and Motor Function in Individuals With Parkinson's Disease
Parkinson Disease
Primary: Change in Right Insula-dorsomedial Frontal Cortex Functional Connectivity Strength. — 93.2; 97.8 percent change from baseline — p=0.981
N/A N=188 STEM-Parkinson's Disease
Parkinson Disease · Parkinson's Disease and Parkinsonism
Primary: Change in The International Parkinson and Movement Disorder Society Non-Motor Rating Scale (MDS-NMS) Total Score — -21.2; -18.3 score on a scale
N/A N=61 rTMS for Motor and Mood Symptoms of Parkinson's Disease
Parkinson's Disease · Depression
Primary: Motor Subscale of the Unified Parkinson's Disease Rating Scale (UPDRS Part III) — 32.3; 33.1; 32.8; 28.9 units on a scale
N/A N=22 Adaptive Closed Loop Neuromodulation and Neural Signatures of Parkinson's Disease
Parkinson's Disease
Primary: Normalized Beta Band Power (13-30 Hz) During aDBS — 0.26 Normalized median beta power — p=<0.001
Phase 4 N=359 Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
Parkinson's Disease With End of Dose Wearing Off
Primary: Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 4 — -3.7; -1.8 Units on a scale
N/A N=2,448 First Presentation of Parkinson Disease Patients to Neurologist
Parkinson Disease
Primary: Number of De-novo Patients in Whom Monotherapy With Mirapexin® Could be Successfully Initiated — 403; 323; 73; 15 Participants
Early Phase 1 N=54 Cognitive Rehabilitation in Parkinson's Disease
Parkinson's Disease
Primary: Reaction Time and Variability for Movement Task — 1013.858333; 994.94875; 979.2450877; 910.9120833 milliseconds
N/A N=7 Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease
Parkinson Disease · Brain Stimulation · Cerebellum
Primary: Speed Walked During 30 Meter Walk Test — 5.63; 5.65; 5.77; 5.86 meters per second (m/s)
Phase 3 N=496 Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
Parkinson Disease
Primary: Evaluation of Safety and Tolerability Data Collected, Based on Number of Participants With Adverse Events in the LTS Phase — 365 Participants